{
    "clinical_study": {
        "@rank": "93897", 
        "arm_group": {
            "arm_group_label": "Experimental", 
            "arm_group_type": "Experimental", 
            "description": "ONO-4059"
        }, 
        "brief_summary": {
            "textblock": "This is an open-label, multi-centre, phase I dose-escalation study to investigate the safety\n      and tolerability of ONO-4059 given as monotherapy to patients with relapsed/refractory NHL\n      and CLL. ONO-4059 will be administered orally, once daily(QD)as a flat dose, for up to\n      maximum 24 cycles of treatment."
        }, 
        "brief_title": "Phase I Study of ONO-4059 Given as Monotherapy in Patients With Relapsed/Refractory NHL and CLL", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Non Hodgkins Lymphoma", 
            "Chronic Lymphocytic Leukaemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "detailed_description": {
            "textblock": "An open-label, multi-centre, non-randomised phase I dose-escalation study to investigate the\n      safety and tolerability of ONO-4059 given as monotherapy in patients with\n      relapsed/refractory Non-Hodgkin's lymphoma (NHL) and relapsed/refractory chronic lymphocytic\n      leukaemia (CLL). Non-Hodgkin's lymphoma are a heterogeneous group of malignancies which have\n      a varied clinical and biological features. Leukaemia is a type of cancer of the blood or\n      bone marrow characterized by an abnormal increase of immature white blood cells. Chronic\n      lymphocytic leukaemia (CLL) is the most common type of adult leukaemia affecting the blood\n      and bone marrow."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Males or females with a confirmed diagnosis of and documented history of relapsed or\n             refractory malignant disease (B-cell lymphoma and/or CLL) for which no therapy of\n             curative or high priority exists and for whom treatment with a Btk inhibitor may be\n             deemed appropriate.\n\n          2. Age \u226518 years.\n\n          3. Eastern Cooperative Oncology Group (ECOG) performance status of \u22642.\n\n        Exclusion Criteria:\n\n          1. Central nervous system (CNS) lymphoma.\n\n          2. Women who are pregnant or lactating."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01659255", 
            "org_study_id": "ONO-4059POE001"
        }, 
        "intervention": {
            "arm_group_label": "Experimental", 
            "description": "ONO-4059 QD up to maximum 24 cycles (1 cycle = 28 days). Start dose is 20mg.", 
            "intervention_name": "ONO-4059", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 22, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Morschhauser", 
                    "phone": "+33 3 20444290"
                }, 
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59037"
                    }, 
                    "name": "CHRU - Hopital Claude HURIEZ"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Salles", 
                    "phone": "+33 4 7886 4307"
                }, 
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69495"
                    }, 
                    "name": "Centre hospitalier Lyon Sud"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Cartron", 
                    "phone": "+33-4-67338079"
                }, 
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France", 
                        "zip": "34295"
                    }, 
                    "name": "CHU St Eloi"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Fegan", 
                    "phone": "+44 (0)2920 745654"
                }, 
                "facility": {
                    "address": {
                        "city": "Cardiff", 
                        "country": "United Kingdom", 
                        "zip": "CF14 4XW"
                    }, 
                    "name": "University Hospital of Wales"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dyer", 
                    "phone": "+44-(0)116-252-5589"
                }, 
                "facility": {
                    "address": {
                        "city": "Leicester", 
                        "country": "United Kingdom", 
                        "zip": "LE1 5WW"
                    }, 
                    "name": "Leicester Royal Infirmary"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Rule", 
                    "phone": "+44 (0)1752 517505"
                }, 
                "facility": {
                    "address": {
                        "city": "Plymouth", 
                        "country": "United Kingdom", 
                        "zip": "PL6 8DH"
                    }, 
                    "name": "Derriford Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Dose-escalation Study to Investigate the Safety and Tolerability of ONO-4059 Given as Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma and/or Chronic Lymphocytic Leukaemia.", 
        "overall_contact": {
            "last_name": "Ono Pharma UK Ltd"
        }, 
        "overall_official": {
            "affiliation": "Ono Pharmaceutical Co. Ltd", 
            "last_name": "Clinical Department", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Frequency, severity and relatedness of AEs.", 
            "measure": "1. Safety and tolerability and the incidence of dose limiting toxicities (DLTs). DLTs will be assessed within the first 28 days from receiving the first dose of ONO-4059.", 
            "safety_issue": "Yes", 
            "time_frame": "6 - 24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01659255"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Pharmacodynamics of ONO-4059 (ie, drug occupancy of Btk and effect on biological markers of B cell function.", 
                "measure": "1. Pharmacokinetic/pharmacodynamic assessments", 
                "safety_issue": "No", 
                "time_frame": "During 1 cycle = 28 days"
            }, 
            {
                "description": "Overall response rate as defined by guidelines on NHL and CLL, duration of response, CR rate, PFS, OS", 
                "measure": "2. Tumour response", 
                "safety_issue": "No", 
                "time_frame": "Cycles 3 and 6, 9, 12, 18, 24 (28 days for each cycle)."
            }
        ], 
        "source": "Ono Pharmaceutical Co. Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ono Pharmaceutical Co. Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}